US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
pharma · Acute Myeloid Leukemia · Relapsed and/or refractory Acute Myeloid Leukemia · KURA
Kura Oncology
Kura Oncology drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
12730 High Bluff Dr, Suite 400, San Diego, California 92130, US HQ
2014 Founded
313 Employees
Public company Type
KURA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 12730 High Bluff Dr, Suite 400, San Diego, California 92130, US
- Founded
- 2014
- Employees
- 313
- Programs
- 25
- Drugs
- 14
- Patents
- 132
Kura Oncology pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kura Oncology drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Kura Oncology in public FDA and regional records.
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Kura Oncology in public FDA and regional records.
-
Development asset linked to Kura Oncology in public FDA and regional records.
-
Development asset linked to Kura Oncology in public FDA and regional records.
-
Development asset linked to Kura Oncology in public FDA and regional records.
-
Development asset linked to Kura Oncology in public FDA and regional records.
-
Development asset linked to Kura Oncology in public FDA and regional records.
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor
-
US regulatory status: approved.